Curanex Pharmaceuticals INC S-1 registration statements

Curanex Pharmaceuticals Inc., a developmental stage company focused on botanical drugs, is launching an initial public offering of 3.75 million shares to raise approximately $12.1 million, aiming to advance its lead candidate Phyto-N into clinical trials for ulcerative colitis and other inflammatory conditions.

Curanex Pharmaceuticals Inc., a developmental stage company focused on botanical drugs for inflammatory diseases, has filed an S-1/A amendment for its initial public offering to raise up to $15 million, while also extending the maturity date of a significant related-party promissory note.

Curanex Pharmaceuticals aims to raise $10 million through an IPO to fund the development of its lead botanical drug candidate, Phyto-N, and expand its research into inflammatory diseases.

Curanex Pharmaceuticals is seeking to raise capital through a $10 million IPO to fund the clinical development of its lead botanical drug candidate, Phyto-N, and pursue Nasdaq listing.

Curanex Pharmaceuticals has filed an amended registration statement for an initial public offering of 2,000,000 shares and a secondary offering of up to 1,750,000 shares by selling stockholders.

Curanex Pharmaceuticals amends its S-1 filing, detailing an IPO of 2,000,000 shares and a resale of up to 1,750,000 shares by a selling stockholder, along with updates to its incentive compensation recovery policy.

Curanex Pharmaceuticals aims to raise $24.3 million through an initial public offering to fund the clinical development of its lead botanical drug candidate, Phyto-N, and other research initiatives.